HRP20050557A2 - Method for improving the pharmacokinetics of a nnrti - Google Patents

Method for improving the pharmacokinetics of a nnrti

Info

Publication number
HRP20050557A2
HRP20050557A2 HR20050557A HRP20050557A HRP20050557A2 HR P20050557 A2 HRP20050557 A2 HR P20050557A2 HR 20050557 A HR20050557 A HR 20050557A HR P20050557 A HRP20050557 A HR P20050557A HR P20050557 A2 HRP20050557 A2 HR P20050557A2
Authority
HR
Croatia
Prior art keywords
nnrti
pharmacokinetics
improving
hiv
infection
Prior art date
Application number
HR20050557A
Other languages
English (en)
Croatian (hr)
Inventor
Graham Cordingley Michael
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20050557A2 publication Critical patent/HRP20050557A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20050557A 2002-12-16 2005-06-15 Method for improving the pharmacokinetics of a nnrti HRP20050557A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16
PCT/EP2003/014224 WO2004054586A1 (en) 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Publications (1)

Publication Number Publication Date
HRP20050557A2 true HRP20050557A2 (en) 2006-05-31

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050557A HRP20050557A2 (en) 2002-12-16 2005-06-15 Method for improving the pharmacokinetics of a nnrti

Country Status (20)

Country Link
US (2) US20040152625A1 (ko)
EP (1) EP1575595A1 (ko)
JP (1) JP2006511538A (ko)
KR (1) KR20050085681A (ko)
CN (1) CN1726041A (ko)
AU (1) AU2003296647A1 (ko)
BR (1) BR0317095A (ko)
CA (1) CA2510143A1 (ko)
EA (1) EA200500894A1 (ko)
EC (1) ECSP055854A (ko)
HR (1) HRP20050557A2 (ko)
IL (1) IL169099A0 (ko)
MX (1) MXPA05005773A (ko)
NO (1) NO20053455L (ko)
NZ (1) NZ541187A (ko)
PL (1) PL376900A1 (ko)
RS (1) RS20050461A (ko)
UA (1) UA81003C2 (ko)
WO (1) WO2004054586A1 (ko)
ZA (1) ZA200502947B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
CN101405293B (zh) 2005-11-30 2013-03-13 中裕新药股份有限公司 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
EP2064177B1 (en) 2006-09-21 2017-04-05 TaiMed Biologics, Inc. Protease inhibitors
EP2400846B1 (en) 2009-02-27 2016-10-05 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
RU2591830C2 (ru) 2009-04-25 2016-07-20 Ф. Хоффманн-Ля Рош Аг Способы улучшения фармакокинетики
US8936781B2 (en) 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2285577A1 (en) * 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
US6147095A (en) * 1998-11-04 2000-11-14 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
ATE331716T1 (de) * 2002-09-19 2006-07-15 Boehringer Ingelheim Ca Ltd Nicht-nukleosidische inhibitoren der reverse transkriptase

Also Published As

Publication number Publication date
KR20050085681A (ko) 2005-08-29
NZ541187A (en) 2007-12-21
NO20053455L (no) 2005-08-10
BR0317095A (pt) 2005-10-25
EP1575595A1 (en) 2005-09-21
US20040152625A1 (en) 2004-08-05
CA2510143A1 (en) 2004-07-01
US20080096832A1 (en) 2008-04-24
EA200500894A1 (ru) 2006-02-24
ZA200502947B (en) 2008-01-30
UA81003C2 (en) 2007-11-26
RS20050461A (en) 2007-08-03
IL169099A0 (en) 2007-07-04
ECSP055854A (es) 2006-01-16
CN1726041A (zh) 2006-01-25
AU2003296647A1 (en) 2004-07-09
JP2006511538A (ja) 2006-04-06
WO2004054586A1 (en) 2004-07-01
MXPA05005773A (es) 2005-08-16
PL376900A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
HRP20050557A2 (en) Method for improving the pharmacokinetics of a nnrti
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
DK0871465T3 (da) Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS
CY1110690T1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200601654A1 (ru) Ингибиторы интегразы вич
GEP20063783B (en) N-Phenpropylcyclopentyl-Substituted Glutaramide Derivatives as Inhibitors of Neutral Endopeptidase Enzyme (NEP) for Treating Female Sexual Dysfunction (FSAD)
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
WO2005028479A3 (en) Hiv replication inhibiting purine derivatives
ATE373005T1 (de) Thienopyrrole als antivirale mittel
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
NL1024676A1 (nl) HIV integrase-remmers, farmaceutische preparaten en methoden voor het gebruik daarvan.
MX2021016149A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
NO20055518L (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
NO20051261L (no) Morfin-6-glukuronidsalt
DK1053012T3 (da) Farmaceutiske sammensætninger omfattende PEG-asparaginase til behandling af HIV-infektioner
MX2022011885A (es) Composicion farmaceutica para la prevencion o tratamiento de enfermedad infecciosa viral de arn epidemica.
HUP0401091A2 (hu) Atazanavir alkalmazása HIV-terápiában
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071213

Year of fee payment: 5

OBST Application withdrawn